Last updated on August 2019

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Clinical Study Identifier: NCT03123588

Find a site near you

Start Over

Vidant Medical Center

Greenville, NC United States
  Connect »